Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...

Eli Lilly should become a much bigger money machine with multiple growth drivers in its product lineup and a promising ...

That's the folks in the weight loss drug space after a monster 2022, 2023, Eli Lilly, of which I'm a shareholder ... Any non investing related discoveries a book, a band, a movie that you would want ...

With the familiar voices of Kingsley Marshall, Keegan Hedley, Shayle Simons, Lilly Bartlam, and Ron Pardo, the voice cast is further enriched by stars like Iain Armitage, Marsai Martin, Yara Shahidi, ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast. This tepid outlook adds to ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...